文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺癌切除术后辅助放疗与早期挽救放疗的长期结果:单中心大样本经验

Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience.
PubMed 文献 · Pract Radiat Oncol · 2016-10-19

该回顾性单中心研究纳入1992至2013年间171例接受辅助放疗(ART)和230例接受早期挽救放疗(ESRT,PSA≤0.5 ng/mL)且具有不良病理特征(pT3和/或切缘阳性)的前列腺癌患者。中位随访7.4和8.0年,ART组10年无生化失败生存(FFBF)和无雄激素剥夺治疗生存(FFADT)均优于ESRT组,但远处转移和总生存无显著差异;倾向性评分匹配后ART仍与FFBF、FFADT及无远处转移生存改善相关。

要点

  • 回顾性设计,ART的FFBF获益仅在假设38%的ART患者被手术治愈并剔除后失去统计学意义。

核心结论

  • 术后放疗可获得优异的长期肿瘤控制,ART可能与FFBF、FFADT及FFDM改善相关,但OS相当。

研究设计与样本

  • 回顾性单中心研究,纳入1992至2013年间718例术后放疗患者中的171例ART和230例ESRT(PSA≤0.5 ng/mL),均具有不良病理特征(pT3和/或切缘阳性)。

主要发现

  • 敏感性分析显示,仅当假设38%的ART患者被手术治愈并剔除后,ART的FFBF获益才失去统计学意义。

关键数值与推荐

  • 生化失败定义为PSA≥0.2 ng/mL;ESRT定义为PSA≤0.5 ng/mL时放疗。
  • ART组10年FFBF 69%、FFADT 88%;ESRT组10年FFBF 56%、FFADT 81%。

临床怎么用

  • 对于pT3和/或切缘阳性的前列腺癌术后患者,ART可能改善生化控制及无远处转移生存,但需结合回顾性证据谨慎权衡。

局限性

  • 回顾性研究设计,存在选择偏倚,结论需谨慎解读,最佳放疗时机尚待前瞻性试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate freedom from biochemical failure (FFBF), freedom from androgen deprivation therapy (FFADT), freedom from distant metastases (FFDM), and overall survival (OS) after adjuvant radiation therapy (ART) versus early salvage radiation therapy (ESRT) in men with prostate cancer and adverse pathologic features (pT3 and/or positive surgical margins). METHODS AND MATERIALS: Of 718 patients consecutively treated with postoperative radiation therapy (RT) for prostate cancer between 1992 and 2013, we retrospectively identified 171 men receiving ART and 230 receiving ESRT (RT delivered at a prostate-specific antigen level ≤0.5 ng/mL) who had adverse pathologic features. Postirradiation FFBF (BF was defined as prostate-specific antigen level rise to ≥0.2 ng/mL), FFADT, FFDM, and OS were compared using Kaplan-Meier and Cox regression methods. Propensity score (PS)-matching was performed to estimate treatment effects while accounting for covariates predicting treatment allocation. RESULTS: Median follow-up was 7.4 and 8.0 years for patients treated with ART and ESRT, respectively. Ten-year FFBF (69% vs 56%, P = .003) and 10-year FFADT (88% vs 81%, P = .046) rates were higher after ART; however, FFDM and OS did not significantly differ. After PS-matching, ART was associated with improved FFBF (P < .0001), FFADT (P = .0001), and FFDM (P = .02). Findings were confirmed in multivariable analyses in unmatched and PS-matched cohorts. Sensitivity analyses showed that FFBF benefit associated with ART lost statistical significance only after 38% of ART patients were assumed to have been cured by surgery and excluded from the model. This corresponds to the upper bound of patients with adverse pathologic features who did not recur after observation in prior randomized trials. CONCLUSIONS: Postoperative RT confers excellent long-term cancer control. These results suggest ART may be associated with improved FFBF, FFADT, and FFDM, but comparable OS. Given the retrospective study design, these findings should be interpreted with caution. Optimal timing of postoperative RT further awaits results of ongoing trials.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Buscariollo DL, Drumm M, Niemierko A, et al. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol. 2016. PMID: 28274403. doi:10.1016/j.prro.2016.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。